Dermatitis, Atopic (ATOD)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Dermatitis, Atopic

MalaCards integrated aliases for Dermatitis, Atopic:

Name: Dermatitis, Atopic 57 6 44 39 70
Atopic Dermatitis 12 73 43 36 15 32
Atopic Eczema 12 43 15 17
Dermatitis, Atopic, Susceptibility to, 1 57 29 13
Atopic Neurodermatitis 12
Dermatitis, Atopic 1 57
Allergic Dermatitis 12
Besnier's Prurigo 12
Dermatitis Atopic 54
Eczema, Atopic 57
Eczema 70
Atod 57



57 (Updated 20-May-2021)
food intolerance
diagnosis requires 3 major features (a positive family history is also considered a major feature) and at least 3 minor features

autosomal dominant


dermatitis, atopic:
Inheritance autosomal dominant inheritance


Summaries for Dermatitis, Atopic

MedlinePlus Genetics : 43 Atopic dermatitis (also known as atopic eczema) is a disorder characterized by inflammation of the skin (dermatitis). The condition usually begins in early infancy, and it often disappears before adolescence. However, in some affected individuals the condition continues into adulthood; in others, it does not begin until adulthood. Hallmarks of atopic dermatitis include dry, itchy skin and red rashes that come and go. The rashes can occur on any part of the body, although the pattern tends to be different at different ages. In affected infants, the rashes commonly occur on the face, scalp, hands, and feet. In children, the rashes are usually found in the bend of the elbows and knees and on the front of the neck. In adolescents and adults, the rashes typically occur on the wrists, ankles, and eyelids in addition to the bend of the elbows and knees. Scratching the itchy skin can lead to oozing and crusting of the rashes and thickening and hardening (lichenification) of the skin. The itchiness can be so severe as to disturb sleep and impair a person's quality of life.The word "atopic" indicates an association with allergies. While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies. Atopic dermatitis is often the beginning of a series of allergic disorders, referred to as the "atopic march." Development of these disorders typically follows a pattern, beginning with atopic dermatitis, followed by food allergies, then hay fever, and finally asthma. However, not all individuals with atopic dermatitis will progress through the atopic march, and not all individuals with one allergic disease will develop others.Individuals with atopic dermatitis have an increased risk of developing other conditions related to inflammation, such as inflammatory bowel disease, rheumatoid arthritis, and hair loss caused by a malfunctioning immune reaction (alopecia areata). They also have an increased risk of having a behavioral or psychiatric disorder, such as attention-deficit/hyperactivity disorder (ADHD) or depression.In a particular subset of individuals with atopic dermatitis, the immune system is unable to protect the body from foreign invaders such as bacteria and fungi (which is known as immunodeficiency). These individuals are prone to recurrent infections. Most also have other allergic disorders, such as asthma, hay fever, and food allergies.Atopic dermatitis can also be a feature of separate disorders that have a number of signs and symptoms, which can include skin abnormalities and immunodeficiency. Some such disorders are Netherton syndrome; immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome; and severe dermatitis, multiple allergies, metabolic wasting (SAM) syndrome.

MalaCards based summary : Dermatitis, Atopic, also known as atopic dermatitis, is related to dermatitis, atopic, 3 and eczema herpeticum, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis, Atopic is FLG (Filaggrin), and among its related pathways/superpathways are Allograft rejection and JAK-STAT signaling pathway. The drugs Zinc oxide and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and breast, and related phenotypes are cataract and ichthyosis

Disease Ontology : 12 An allergic contact dermatitis that is a chronically relapsing inflammatory allergic response located in the skin that causes itching and flaking.

OMIM® : 57 Atopic dermatitis (ATOD), also known as eczema, is a common chronic pruritic inflammatory skin disease with a strong genetic component. Onset typically occurs during the first 2 years of life (review by Soderhall et al., 2007). (603165) (Updated 20-May-2021)

KEGG : 36 Atopic dermatitis (AD) is a relapsing chronic inflammatory skin disease characterized by eczematous skin lesions and intense pruritus. A genetic defect in the filaggrin (FLG) protein and/or environmental factors are thought to cause AD by disrupting the epidermis. This disruption, in turn, results in contact between immune cells in the dermis and antigens from the external environment leading to intense itching, scratching, and inflammation. Apart from FLG, recent genome-wide association studies (GWASs) have identified many susceptibility loci of atopic dermatitis with genome-wide significance.

Wikipedia : 73 Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin... more...

Related Diseases for Dermatitis, Atopic

Diseases in the Dermatitis, Atopic family:

Dermatitis, Atopic, 2 Dermatitis, Atopic, 3
Dermatitis, Atopic, 4 Dermatitis, Atopic, 5
Dermatitis, Atopic, 6 Dermatitis, Atopic, 7
Dermatitis, Atopic, 8 Dermatitis, Atopic, 9

Diseases related to Dermatitis, Atopic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 892)
# Related Disease Score Top Affiliating Genes
1 dermatitis, atopic, 3 33.2 TSLP ATOD3
2 eczema herpeticum 32.9 TSLP IL4 IFNG FLG
3 egg allergy 32.9 TSLP IL5 IL4 IL13 FLG
4 milk allergy 32.8 RNASE3 IL5 IL4 IL13
5 pollen allergy 32.8 RNASE3 IL5 IL13
6 allergic disease 32.8 TSLP RNASE3 IL5 IL4 IL13 IFNG
7 allergic asthma 32.7 TSLP RNASE3 IL5 IL4 IL13 IFNG
8 hyper ige syndrome 32.7 RNASE3 IL4 IL13 IFNG
9 conjunctivitis 32.4 RNASE3 IL5 IL4 IL13 IFNG
10 hypereosinophilic syndrome 32.4 RNASE3 IL5 IL4 IL13 IFNG CCL17
11 cytokine deficiency 32.3 IL5 IL13
12 proteasome-associated autoinflammatory syndrome 1 32.1 RNASE3 IL5 IL4 IL13 IFNG
13 alopecia areata 32.0 IL4 IL13 IFNG FLG
14 dermatitis 31.9 TSLP SPINK5 RNASE3 IL5 IL4 IL31
15 allergic conjunctivitis 31.9 RNASE3 IL5 IL4 IL13 IFNG
16 keratoconjunctivitis 31.8 TSLP RNASE3 IL5 IL4 IL13 IFNG
17 cutaneous t cell lymphoma 31.8 IL5 IL4 IFNG CCL17
18 peanut allergy 31.8 IL5 IL4 IL13 IFNG FLG CCL22
19 chronic urticaria 31.8 RNASE3 IL4 IL13
20 chronic spontaneous urticaria 31.7 TSLP IL31 IFNG
21 bronchitis 31.7 RNASE3 IL5 IL4 IL13
22 mycosis fungoides 31.7 MIR155 IL5 IFNG CCL22 CCL17
23 esophagitis 31.7 TSLP RNASE3 IL5 IL4 IL13 FLG
24 esophagitis, eosinophilic, 1 31.7 TSLP RNASE3 IL5 IL4 IL13 FLG
25 folliculitis 31.7 IL5 IL4 IFNG
26 tetanus 31.7 IL5 IL4 IL13 IFNG
27 lichen planus 31.6 IL4 IFNG FLG
28 atopic keratoconjunctivitis 31.6 RNASE3 IL5 IL4 IFNG CCL22
29 celiac disease 1 31.5 IL5 IL4 IL13 IFNG
30 skin disease 31.4 TSLP SPINK5 RNASE3 MIR155 IL5 IL4
31 otitis media 31.4 RNASE3 IL5 IL4 IFNG
32 pemphigoid 31.3 IL5 IL4 IL13 IFNG
33 bullous pemphigoid 31.3 RNASE3 IL5 IL4 IL13 CCL17
34 contact dermatitis 31.3 IL5 IL4 IL31 IFNG FLG CCL22
35 bronchiolitis 31.3 RNASE3 IL5 IL4 IL13 IFNG
36 ascaris lumbricoides infection 31.3 TSLP IL5 IL13 IFNG
37 diphtheria 31.2 IL5 IL4 IL13
38 dermatitis herpetiformis 31.2 IL5 IL4 IL31
39 allergic contact dermatitis 31.2 IL5 IL4 IL31 IFNG FLG CCL22
40 latex allergy 31.2 RNASE3 IL5 IL4 IL13 IFNG FLG
41 food allergy 31.2 SPINK5 RNASE3 IL5 IL4 IL13 IFNG
42 cow milk allergy 31.2 IL5 IL4
43 respiratory failure 31.2 RNASE3 IL5 IL13 CCL17
44 acute asthma 31.1 RNASE3 IL5 IL4
45 pulmonary disease, chronic obstructive 31.1 RNASE3 IL5 IL4 IL13
46 conjunctival disease 31.1 TSLP RNASE3 IL5 IL4 IL13 IFNG
47 neurodermatitis 31.1 TSLP IL4 IL31 IL13 FLG
48 ige responsiveness, atopic 31.1 SPINK5 RNASE3 IL5 IL4 IL13 IFNG
49 chronic conjunctivitis 31.1 TSLP RNASE3 IL5 IL4 IL13
50 schistosomiasis 31.1 RNASE3 IL5 IL4 IL13 IFNG

Graphical network of the top 20 diseases related to Dermatitis, Atopic:

Diseases related to Dermatitis, Atopic

Symptoms & Phenotypes for Dermatitis, Atopic

Human phenotypes related to Dermatitis, Atopic:

31 (show all 18)
# Description HPO Frequency HPO Source Accession
1 cataract 31 HP:0000518
2 ichthyosis 31 HP:0008064
3 dry skin 31 HP:0000958
4 pallor 31 HP:0000980
5 asthma 31 HP:0002099
6 conjunctivitis 31 HP:0000509
7 eczema 31 HP:0000964
8 abnormality of metabolism/homeostasis 31 HP:0001939
9 keratoconus 31 HP:0000563
10 pruritus 31 HP:0000989
11 recurrent skin infections 31 HP:0001581
12 atopic dermatitis 31 HP:0001047
13 food intolerance 31 HP:0012537
14 infra-orbital fold 31 HP:0011232
15 facial erythema 31 HP:0001041
16 allergic rhinitis 31 HP:0003193
17 keratosis pilaris 31 HP:0032152
18 flexural lichenification 31 HP:0007453

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Skin Nails Hair Skin:
facial erythema
keratosis pilaris
palmar hyperlinearity
Head And Neck Nose:
allergic rhinitis

elevated ige

Head And Neck Eyes:
cataracts (anterior- subcapsular)
conjunctivitis (recurrent)
orbital darkening

Respiratory Airways:
bronchial asthma

Laboratory Abnormalities:
immediate (type i) skin test reactivity

Clinical features from OMIM®:

603165 (Updated 20-May-2021)

UMLS symptoms related to Dermatitis, Atopic:

pruritus; exanthema

Drugs & Therapeutics for Dermatitis, Atopic

Drugs for Dermatitis, Atopic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 333)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Zinc oxide Approved Phase 4 1314-13-2
Coal tar Approved Phase 4 8007-45-2
Omalizumab Approved, Investigational Phase 4 242138-07-4
Glycerol Approved, Investigational Phase 4 56-81-5 753
Desonide Approved, Investigational Phase 4 638-94-8 5311066
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
carbamide peroxide Approved Phase 4 124-43-6
Montelukast Approved Phase 4 158966-92-8 5281040
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Levocetirizine Approved Phase 4 130018-77-8 1549000
Desoximetasone Approved Phase 4 382-67-2 5311067
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Alitretinoin Approved, Investigational Phase 4 5300-03-8 444795 449171
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
Cortisone Experimental Phase 4 53-06-5 222786
Halometasone Experimental Phase 4 50629-82-8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
36 Keratolytic Agents Phase 4
37 Protective Agents Phase 4
38 Hormones Phase 4
39 Sodium hypochlorite Phase 4
40 Eusol Phase 4
41 Hormone Antagonists Phase 4
42 glucocorticoids Phase 4
43 Bronchodilator Agents Phase 4
44 Antimetabolites Phase 4
45 Hypolipidemic Agents Phase 4
46 Lipid Regulating Agents Phase 4
47 Leukotriene Antagonists Phase 4
48 Epinephryl borate Phase 4
49 Histamine H1 Antagonists, Non-Sedating Phase 4
50 Evening Primrose Phase 4

Interventional clinical trials:

(show top 50) (show all 1001)
# Name Status NCT ID Phase Drugs
1 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
2 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
3 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
4 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
5 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
6 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
7 Effect of Sublingual Immunotherapy With Mite Extract in Patients With Atopic Dermatits: Placebo-controlled Double-blind Randomized Study Completed NCT03388866 Phase 4 Mite extract sublingual immunotherapy (SLIT)
8 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A
9 Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing Effect of Epiceram™ Device vs Standard of Care Therapy of Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) in Treatment of Atopic Dermatitis in Pediatric Subjects Completed NCT00616538 Phase 4 Fluticasone Propionate 0.05%
10 Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
11 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
12 Proactive Treatment With Tacrolimus Ointment in Children With Moderate/Severe Atopic Dermatitis: A Randomized, Multicenter, Open-label Study Completed NCT01745159 Phase 4 tacrolimus
13 Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis Completed NCT01148667 Phase 4
14 A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents Completed NCT00568412 Phase 4 Elidel
15 An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
16 A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
17 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
18 A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
19 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
20 Quality of Life Study in Adults With Facial Eczema Completed NCT00120302 Phase 4 Pimecrolimus;Placebo
21 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
22 A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment Completed NCT00673725 Phase 4 Locobase® REPAIR
23 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
24 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
25 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
26 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
27 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
28 An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis Completed NCT01093469 Phase 4 Atopiclair Nonsteroidal Cream;EpiCeram
29 Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study Completed NCT01064947 Phase 4 Retapamulin 1%
30 An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed NCT01049243 Phase 4 Fluocinonide Cream 0.1%
31 Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
32 Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study) Completed NCT00878670 Phase 4 EPOGAM 1000
33 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
35 A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
36 A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis Completed NCT00510003 Phase 4 Pimecrolimus
37 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
38 Randomized, Double Blind, Controlled Trial on Effectiveness Combined Probiotics in the Treatment of Atopic Dermatitis in Children Completed NCT02519556 Phase 4 Probiatop;Placebo
39 Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis Completed NCT01077882 Phase 4
40 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
41 Non-comparative Open-label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion Completed NCT00925730 Phase 4 Pimecrolimus
42 Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis Completed NCT00819507 Phase 4 Fluocinonide
43 Transepidermal Water Loss (TEWL) and Corneometry With Hydrogel Vehicle in the Treatment of Atopic Dermatitis - A Randomized, Investigator-Blind Pilot Study Completed NCT01065714 Phase 4 Hydrogel vehicle;Eucerin Lotion
44 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
45 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
46 Short Term Growth in Children With Atopic Dermatitis Completed NCT00236106 Phase 4 tacrolimus ointment 0.1%;mometasone furoate 0.1%
47 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
48 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
49 An Exploratory Double-blind, Randomized, Vehicle-controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Elidel Cream 1% and Cutivate Cream 0.05% in Patients With Severe Lesions of Atopic Dermatitis (AD) Completed NCT00119158 Phase 4 Combination of pimecrolimus and fluticasone;pimecrolimus
50 Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods Completed NCT00180141 Phase 4 Elidel-Creme

Search NIH Clinical Center for Dermatitis, Atopic

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
Doxepin Hydrochloride
Fluocinolone Acetonide
Methdilazine hydrochloride
trimeprazine tartrate
Triprolidine Hydrochloride
Zinc Oxide

Cochrane evidence based reviews: dermatitis, atopic

Genetic Tests for Dermatitis, Atopic

Genetic tests related to Dermatitis, Atopic:

# Genetic test Affiliating Genes
1 Dermatitis, Atopic, Susceptibility to, 1 29

Anatomical Context for Dermatitis, Atopic

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatitis, Atopic:


MalaCards organs/tissues related to Dermatitis, Atopic:

Skin, T Cells, Breast, Thymus, Monocytes, Brain, Bone

Publications for Dermatitis, Atopic

Articles related to Dermatitis, Atopic:

(show top 50) (show all 21816)
# Title Authors PMID Year
A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis. 61 54 57
17441792 2007
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. 54 61 6
16550169 2006
A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. 61 57 54
11101848 2000
Linkage of atopic dermatitis to chromosomes 4q22, 3p24 and 3q21. 61 57
19517137 2009
Atopic dermatitis. 57 61
18385500 2008
Variants in a novel epidermal collagen gene (COL29A1) are associated with atopic dermatitis. 61 57
17850181 2007
Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. 6 61
16815158 2006
Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. 61 57
12045207 2002
Linkage and association to candidate regions in Swedish atopic dermatitis families. 57 61
11511916 2001
Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. 61 57
11279517 2001
Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. 61 57
11069631 2000
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. 61 47
20673989 2010
Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. 6
17030239 2006
Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. 6
16444271 2006
Mosaic atopic eczema cured by autotransplantation? 57
9752825 1998
The prevalence of childhood atopic eczema in a general population. 57
8277028 1994
Aetiology of asthma: lessons from lung transplantation. 57
8098790 1993
Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. 57
3059190 1988
Changes in the reported prevalence of childhood eczema since the 1939-45 war. 57
6150286 1984
The lines of Blaschko: a review and reconsideration: Observations of the cause of certain unusual linear conditions of the skin. 57
788770 1976
Sphingosylphosphorylcholine down-regulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. 54 61
20230798 2010
[Safety of azathioprine therapy adjusted to thiopurine methyltransferase activity in the treatment of infantile atopic dermatitis. Report on 7 cases]. 54 61
20525484 2010
Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. 54 61
20466416 2010
Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways. 54 61
20483734 2010
Definition and characterization of an inhibitor for interleukin-31. 54 61
20335179 2010
Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. 54 61
20304960 2010
Impact of heat-inactivated Lactobacillus casei and Lactobacillus paracasei strains on cytokine responses in whole blood cell cultures of children with atopic dermatitis. 54 61
20526842 2010
Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. 54 61
20335530 2010
Analysis of four prevalent filaggrin mutations (R501X, 2282del4, R2447X and S3247X) in Austrian and German patients with atopic dermatitis. 54 61
19874431 2010
[Atopic dermatitis - current insights into path physiology and management]. 61 54
20336617 2010
Sensing the outside world: TSLP regulates barrier immunity. 61 54
20300138 2010
The role of thymic stromal lymphopoietin in allergic inflammation and chronic obstructive pulmonary disease. 54 61
20143171 2010
Association of single nucleotide polymorphisms in the IL-12 (IL-12A and B) and IL-12 receptor (IL-12Rbeta1 and beta2) genes and gene-gene interactions with atopic dermatitis in Koreans. 61 54
20060272 2010
Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. 61 54
20107184 2010
Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. 54 61
20444170 2010
Effects of transmembrane and juxtamembrane domains on proliferative ability of TSLP receptor. 61 54
20096461 2010
Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of life. 54 61
19552791 2010
Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. 54 61
20083663 2010
Genetics of allergic disease. 54 61
20176270 2010
Association of single nucleotide polymorphism of interleukin-18 with atopic dermatitis. 54 61
19453784 2010
Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A. 61 54
19672094 2010
What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies. 54 61
20082953 2010
Human defensins and LL-37 in mucosal immunity. 61 54
19808939 2010
Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production. 54 61
20136617 2010
Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. 54 61
20030614 2010
Thymic stromal lymphopoietin. 61 54
20146705 2010
Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice. 54 61
19818758 2009
Increased pachyonychia congenita severity in patients with concurrent keratin and filaggrin mutations. 61 54
19785597 2009
Inflammatory cytokine tumor necrosis factor-alpha enhances nerve growth factor production in human keratinocytes, HaCaT cells. 61 54
19942804 2009
AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. 54 61
19876791 2009

Variations for Dermatitis, Atopic

ClinVar genetic disease variations for Dermatitis, Atopic:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FLG NM_002016.1(FLG):c.1501C>T (p.Arg501Ter) SNV Pathogenic 16319 rs61816761 GRCh37: 1:152285861-152285861
GRCh38: 1:152313385-152313385
2 KCNJ11 NM_000525.3(KCNJ11):c.185C>G (p.Thr62Arg) SNV Likely pathogenic 373928 rs1057518775 GRCh37: 11:17409454-17409454
GRCh38: 11:17387907-17387907
3 CYP4F22 NM_173483.4(CYP4F22):c.1211T>C (p.Leu404Pro) SNV Uncertain significance 523566 rs1555730246 GRCh37: 19:15658993-15658993
GRCh38: 19:15548182-15548182
4 CYP4F22 NM_173483.4(CYP4F22):c.1544G>T (p.Arg515Leu) SNV Uncertain significance 523567 rs1425964436 GRCh37: 19:15662230-15662230
GRCh38: 19:15551419-15551419

Expression for Dermatitis, Atopic

Search GEO for disease gene expression data for Dermatitis, Atopic.

Pathways for Dermatitis, Atopic

Pathways related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
Show member pathways
12.69 RNASE3 IL5 IL4 IL13 IFNG
Show member pathways
12.25 TSLP IL5 IL4 IL13 IFNG
Show member pathways
12.17 IL5 IL4 IL13 IFNG CCL17
4 11.82 IL5 IL4 IFNG
5 11.8 IL4 IL13 CCL22
6 11.62 IL5 IL4 IL13 IFNG
Show member pathways
11.59 IL5 IL4 IFNG
8 11.5 IL5 IL4 IL13
9 11.49 IL5 IL4 CCL17
10 11.46 TSLP IL5 IL4 IL13 IFNG
11 11.36 IL4 IL13 CCL22
12 11.17 IL5 IL4 IFNG
13 11.09 IL5 IL4 IL13 IFNG
14 10.97 IL5 IL4 IL13 IFNG
15 10.86 IL5 IL4 IL13 CCL22 CCL17
16 10.86 TSLP IL5 IL4 IL13 IFNG
17 10.83 IL5 IL4 IL31 IL13 IFNG CCL22
18 10.62 IL5 IL4 IL13

GO Terms for Dermatitis, Atopic

Cellular components related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TSLP SPINK5 RNASE3 IL5 IL4 IL31
2 extracellular space GO:0005615 9.32 CCL17 CCL22 IFNG IL13 IL31 IL4

Biological processes related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.72 CCL22 IL13 IL31 IL4 IL5
2 positive regulation of inflammatory response GO:0050729 9.71 TSLP MIR155 IFNG
3 positive regulation of B cell proliferation GO:0030890 9.58 IL13 IL4 IL5
4 dendritic cell differentiation GO:0097028 9.55 MIR155 IL4
5 positive regulation of interleukin-10 production GO:0032733 9.54 IL13 IL4 TSLP
6 macrophage activation GO:0042116 9.52 IL4 IL13
7 positive regulation of MHC class II biosynthetic process GO:0045348 9.51 IL4 IFNG
8 positive regulation of interleukin-13 production GO:0032736 9.49 TSLP IL4
9 positive regulation of mast cell degranulation GO:0043306 9.48 IL4 IL13
10 positive regulation of cellular respiration GO:1901857 9.46 IL4 IFNG
11 neuroinflammatory response GO:0150076 9.43 IL4 IFNG
12 immune response GO:0006955 9.43 CCL17 CCL22 IFNG IL13 IL4 IL5
13 microglial cell activation GO:0001774 9.33 IFNG IL13 IL4
14 negative regulation of complement-dependent cytotoxicity GO:1903660 9.26 IL13 IL4
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.92 IFNG IL13 IL4 TSLP

Molecular functions related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 CCL17 CCL22 IFNG IL13 IL31 IL4
2 cytokine receptor binding GO:0005126 9.13 IL4 IL31 IL13

Sources for Dermatitis, Atopic

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....